Business Context and Reporting Period
This Form 8-K, dated July 26, 2011, reports on Accuray Incorporated's completion of a merger with TomoTherapy Incorporated on June 10, 2011. The filing provides preliminary, unaudited financial estimates for Accuray's fiscal year ended June 30, 2011, and TomoTherapy's quarter ended June 30, 2011. TomoTherapy's results are included in Accuray's operations commencing June 10, 2011.
Key Financial Metrics
- Consolidated Revenue (FY 2011): Accuray expects consolidated revenue to be between $221 million and $224 million, including TomoTherapy revenue from June 10 to June 30, 2011.
- Accuray Standalone Revenue (FY 2011): Expected to be between $210 million and $211 million, excluding TomoTherapy.
- TomoTherapy Revenue (Q2 2011): Expected to be between $43 million and $45 million on a stand-alone basis.
- Profit Margins: The filing does not provide specific net income or margin figures. Management expects purchase accounting adjustments to significantly reduce GAAP gross profit compared to pre-adjustment estimates.
- Debt and Liquidity: Accuray proposes to offer $75 million in principal amount of convertible senior notes due 2016, with an option for the initial purchaser to buy up to an additional $11.25 million. Specific liquidity ratios or cash flow figures are not provided in this text.
Material Changes and Accounting Adjustments
The primary material change is the acquisition of TomoTherapy. The reported revenue figures are preliminary and do not reflect purchase accounting adjustments, which could result in higher or lower GAAP revenue. Management anticipates significant purchase accounting impacts, including:
- Inventory and other adjustments that will significantly reduce GAAP gross profit.
- Recording of significant goodwill and intangible assets on the balance sheet.
- Future amortization charges for intangible assets over several years.
Guidance, Outlook, and Risks
Accuray maintains its fiscal 2011 revenue expectation of $210 million to $225 million, though it previously indicated expectations were toward the lower end of that range. The filing highlights several risks and contingencies:
- Unaudited Data: Financial data are management estimates and have not been audited or reviewed by Grant Thornton LLC.
- Accounting Uncertainty: Actual results may differ materially from estimates due to final closing procedures and purchase accounting adjustments.
- Financing Conditions: The proposed $75 million convertible notes offering is subject to market and other conditions.
Investor Verification Checklist
- Verify the final audited consolidated financial statements for the fiscal year ended June 30, 2011, to confirm actual revenue and gross profit after purchase accounting adjustments.
- Review the definitive terms and closing status of the proposed $75 million convertible senior notes offering.
- Examine the valuation of goodwill and intangible assets recorded from the TomoTherapy merger and the associated amortization schedules.
- Confirm the impact of inventory adjustments on the gross profit margin in the final GAAP reporting.